Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

Diabetes, Obesity and Metabolism

Volumn 18, Issue 1, 2016, Pages 92-95

  Drake, T C ^a   Hsu, F C ^b   Hire, D ^b   Chen, S H ^b   Cohen, R M ^c   Mcduffie, R ^d   Nylen, E ^e   O'Connor, P ^f   Rehman, S ^g   Seaquist, E R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f HEALTHPARTNERS INSTITUTE   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Antidiabetic drug; Clinical trial; Cost effectiveness; Diabetes complications; Insulin therapy; Type 2 diabetes

Indexed keywords

GLITAZONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; BLACK PERSON; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HISPANIC; HUMAN; HYPOGLYCEMIA; LETTER; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; WEIGHT CHANGE; WEIGHT GAIN; AGED; ANALYSIS; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; ETHNOLOGY; MIDDLE AGED; REFERENCE VALUE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; REFERENCE VALUES; RISK FACTORS; TREATMENT FAILURE;

EID: 84955193031     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12569     Document Type: Letter

References (15)

1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Ismail-Beigi F, Craven T, Banerji MA et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-430.
4. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
5. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
6. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23: B21-B29.
7. Genuth S, Ismail-Beigi F. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab 2012; 97:41--48.
8. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
9. Gerstein HC, Riddle MC, Kendall DM et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99(Suppl. 12A): 34i-43i.
10. Goff DC, Gerstein HC, Ginsberg HN et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99(Suppl. 12A): 4i-20i.
11. The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99(Suppl. 12A): 21i-33i.
12. Fonseca V, McDuffie R, Calles J et al. Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. Diabetes Care 2013; 36: 2162-2168.
13. Davis TME, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes. Diabetes Care 2001; 24: 1167-1174.
14. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012; 97: 1067-1072.
15. Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD Trial. Diabetes Care 2015; 38: 1067-1074.